$TIL mention timeline

Instil Bio. Every tracked FinTwit mention of $TIL, newest first. 16 mentions since the first on Jul 31, 2025. See the price chart.

January 2026 · 3 mentions

Jan 14
Jacob Plieth — Seven days after $TIL pulled the plug, Immuneonco says it's still independently developing its PD-L1 x VEGF trap palverafusp alfa https://t.co/MVeWhOiLrv $SMMT $BNTX↗
Jan 7
Jacob Plieth — And here's Immuneonco's statement on the $TIL discontinuation. Still says nothing about the reason(s) https://t.co/mX37CLgjz6↗
Jan 6
Jacob Plieth — How many people had $TIL scrapping the Immuneonco deal, discontinuing PD-1 x VEGF, and going back to TIL therapeutics on their #JPM26 bingo card?↗

Oct 16
Jacob Plieth — PD-1 x VEGF news: Shanghai Junshi says it's got FDA approval to start a US ph2/3 trial of JS207 head-to-head vs Opdivo in neoadjuvant NSCLC $SMMT $TIL $BNTX https://t.co/77Fpme5Pvo↗

Sep 7
Jacob Plieth — More doubts for $SMMT as the Harmoni guessing game continues at #WCLC25. Via @ApexOnco -> https://t.co/riemtQP53v $BNTX $TIL $BMY↗

Aug 21
Jacob Plieth — Plus some other #WCLC25 presentations of note: https://t.co/xavXaIItJu $LEGN $TIL $NVS $BNTX $CADL↗
Aug 13
Jacob Plieth — So Immuneonco is presenting AXN-2510/ IMM2510 NSCLC data (apparently only for squamous histology) at #WCLC25. $TIL starting its own US study by year end 2025. $SMMT↗

Jul 31
Jacob Plieth — Did $TIL get a bargain when it bought a PD-L1 x VEGF bispecific from Immuneonco? You decide. Via @ApexOnco -> https://t.co/kwsOLp3y4f $SMMT $BNTX $BMY $PFE $MRK↗
Jul 31
Jacob Plieth — Looking for X-trial comparisons for the $TIL ImmuneOnco data? $RHHBY Impower-150 is one, and here's another: Akeso ph2 ORRs for ivonescimab + chemo from #ELCC24 $SMMT https://t.co/…↗
Jul 31
Jacob Plieth — Seems most of the $TIL PD-L1 x VEGF responses are unconfirmed at this point... why announce now?? $SMMT $BNTX $PFE https://t.co/MJyOCPEbho↗
Jul 31
Jacob Plieth — Here's the original release from Immuneonco -> https://t.co/Vtk9xHyRts Note $TIL IMM2510 / AXN-2510 = palverafusp alfa $SMMT

Jun 2
Jacob Plieth — How $BNTX turned $800m into $1.5bn, via @ApexOnco -> https://t.co/5BVk9OWMYr Who will be next? #ASCO25 $BMY $PFE $SMMT $TIL↗
Jun 2
Jacob Plieth — Well well well (Immuneonco is the originator of $TIL AXN-2510) #ASCO25 https://t.co/MZdekS9acP↗
Jun 2
Jacob Plieth — Just out of interest, here's Huabo's sotiburafusp alfa and $TIL SYN-2510/ AXN-2510. Both are PD-L1 x VEGF-trap fusion proteins. I wonder how strong the IP of each one is #ASCO25 ht…↗
Jun 2
Jacob Plieth — Also: $TIL got passed over by big pharma for the second time in two weeks?? $BNTX $BMY $SMMT $PFE